Figure 3.
Echocardiographic detection of LV dysfunction. (A) Echocardiography in the parasternal long-axis plane at end-diastole and end-systole illustrating an inferoapical WMA (arrow, see online videos for examples of WMAs). (B) Proportion of animals with segmental LV wall motion abnormalities after 1 week of ponatinib therapy. (C-D) Echocardiographic measurement of stroke volume (bars represent mean ± standard deviation) at baseline and after treatment (vehicle or ponatinib) in wild-type (C) and ApoE−/− mice on a WSD (D). ns, not significant.

Echocardiographic detection of LV dysfunction. (A) Echocardiography in the parasternal long-axis plane at end-diastole and end-systole illustrating an inferoapical WMA (arrow, see online videos for examples of WMAs). (B) Proportion of animals with segmental LV wall motion abnormalities after 1 week of ponatinib therapy. (C-D) Echocardiographic measurement of stroke volume (bars represent mean ± standard deviation) at baseline and after treatment (vehicle or ponatinib) in wild-type (C) and ApoE−/− mice on a WSD (D). ns, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal